IDH2 and central nervous system cancer: These findings suggest that TERT promoter mutations may further stratify IDH wild-type gliomas, a subset previously considered to be less sensitive to adjuvant therapies than IDH mutated gliomas, into two subgroups with differential responses to genotoxic therapies.